Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that EGFR p.T790M status confers therapeutic sensitivity to Aumolertinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized aumolertinib as a monotherapy for treatment of adult patients with advanced EGFR T790M mutation-positive non-small cell lung cancer.
This statement is based on a regulatory approval from the European Medicines Agency:
Aumseqa as monotherapy is indicated for the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC.